Key result
Compound 6g potently inhibited the replication of hRV-B14, A21, and A71 with EC50 values of 0.083, 0.078, and 0.015 μM, respectively, by interacting with the viral capsid protein.
Answers are grounded in this paper and cite their sources.
A novel series of benzothiophene derivatives, particularly compound 6g, demonstrated potent in vitro inhibition of rhinovirus and poliovirus replication by targeting the viral capsid protein.
Human rhinoviruses (hRVs) are the main causative pathogen for common colds and are associated with the exacerbation of asthma. The wide variety in hRV serotypes has complicated the development of rhinovirus replication inhibitors. In the current investigation, we developed a novel series of benzothiophene derivatives and their analogues ( 6 – 8 ) that potently inhibit the replication of both hRV-A and hRV-B strains. Compound 6g inhibited the replication of hRV-B14, A21, and A71, with respective EC 50 values of 0.083, 0.078, and 0.015 μM. The results of a time-of-addition study against hRV-B14 and hRV-A16 and resistant mutation analysis on hRV-B14 implied that 6g acts at the early stage of the viral replication process, interacting with viral capsid protein. A molecular docking study suggested that 6g has a capsid-binding mode similar to that of pleconaril. Finally, derivatives of 6 also displayed significant inhibition against poliovirus 3 (PV3) replication, implying their potential inhibitory activities against other enterovirus species.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2017) studied Human rhinovirus infection. Benzothiophene derivatives (Compound 6g) was evaluated on Inhibition of rhinovirus replication (EC50). Compound 6g potently inhibited the replication of hRV-B14, A21, and A71 with EC50 values of 0.083, 0.078, and 0.015 μM, respectively, by interacting with the viral capsid protein.
Synapse has enriched 10 related papers. Consider them for comparative context: